M9
Biopharmaceutics Classification System-based Biowaivers
Current edition
Step 4, 20 November 2019
Current edition
Step 4, 20 November 2019
About this standard
Gives recommendations for the biopharmaceutics classification of medicines and for waiving bioequivalence studies on that basis.
Recognition by market
Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts
- European UnionImplemented
- Edition accepted
- -
- National code
- EMA/CHMP/ICH/493213/2018
Effective July 30, 2020
- JapanImplemented
- Edition accepted
- -
- National code
- PSEHB/PED Notification No. 1225-13
Effective December 25, 2020
- ChinaImplemented
- Edition accepted
- -
- National code
- NMPA, China Announcement No. 61 (2021)
Effective November 7, 2021
- South KoreaImplemented
- Edition accepted
- -
- National code
- -
- 1) Standard on Pharmaceutical Equivalnce Study 2) Guideline on Biopharmaceutics Classification System-based Biowaivers
Effective December 1, 2021
- SingaporeImplemented
- Edition accepted
- -
- National code
- -
- Guidance on Therapeutic Product Registration in Singapore, Appendix 10: Product Interchangeability and Biowaiver Request for Chemical Generic Drug Applications
Effective April 1, 2022
- TaiwanImplemented
- Edition accepted
- -
- National code
- Guideline for Biopharmaceutics Classification System-Based Biowaivers
Effective October 25, 2021
Testing requirements that cite it
Open the market page and its pathway pages for the full requirement, protocol and report content
United States
- Waivers of in vivo bioavailability and bioequivalence studiesBioequivalence · Not stated
European Union
- Biowaivers: BCS-based waivers and waivers for additional strengthsBioequivalence · Not stated
United Kingdom
- Bioequivalence: ICH guidelines implemented by the MHRABioequivalence · Not stated
Japan
- Biowaivers and dosage forms exempt from bioequivalence studiesBioequivalence · Not stated
Canada
- Biowaivers: BCS-based waivers and additional strengthsBioequivalence · Not stated
Australia
- Biowaivers and medicines that do not need biopharmaceutic dataBioequivalence · Not stated
South Korea
- Waivers of bioequivalence studies: BCS, other strengths and exempt dosage formsBioequivalence · Not stated
Switzerland
- Biowaivers and strengths to be examinedBioequivalence · Not stated
Singapore
- Biowaivers: exempt dosage forms, additional strengths and BCS-based waiversBioequivalence · Not stated
- Adoption of ICH guidelines by HSAOther · Not stated
Taiwan
- Waivers of bioequivalence studies and dissolution profile comparisonBioequivalence · Not stated
Related standards: JP guideline for bioequivalence studies of generic products, MHRA comparator product guidance, CPMP/EWP/QWP/1401/98 Rev 1, JP BE guideline, formulation changes (oral solid), NMPA Notice 2016 No. 61, Annex 3, FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M13A. See all standards.